FDA Issues EUA for Novavax COVID-19 Vaccine
7/13/22 — The FDA issued emergency use authorization for the Novavax COVID-19 vaccine, adjuvanted for prevention of COVID-19 in individuals 18 years of age and older. Novavax is administered as a primary series in two doses, three weeks apart. Read more.